Skip to content
DataLookout
Start free
Menu

NCT07831161

Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Start date pushed from Sep 29, 2026 to Nov 29, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: From the first administration of CHANK-101 until disease progression or death from any cause, whichever occurs first, assessed up to Week 48.

Secondary (3)

Number of Participants With Adverse Events as Assessed by NCI-CTCAE Version 5.0
Progression-Free Survival at 6 Months (PFS-6)
Overall Survival (OS)

Arms and interventions

CHANK-101 Treatment GroupExperimental

Participants will receive CHANK-101, an autologous natural killer (NK) cell therapy, by intravenous administration. The first administration will begin 4 to 6 weeks after leukapheresis, or 4 to 6 weeks after surgery for participants undergoing surgical resection of the recurrent lesion. CHANK-101 will subsequently be administered every 2 weeks for up to 12 administrations.

Biologicals: CHANK-101

Sites

4 sites in 1 country